Merck & Co said a therapy it gained through the drugmaker’s $11.5 billion acquisition of Acceleron Pharma last year met the main goal of a late-stage study in patients with a progressive blood vessel disorder.
https://www.pharmalive.com/wp-content/uploads/2021/06/U.S.-signs-1.2-bln-deal-for-1.7-mln-courses-of-Mercks-experimental-COVID-19-drug-Reuters-6-9-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-10-10 08:07:512022-10-10 08:38:45Merck's blood vessel disorder drug succeeds in late-stage study
